98%
921
2 minutes
20
Scarce evidence exists on the demands needed to attain the highest positions during Grand Tours (Giro d'Italia, Tour de France, Vuelta a España). Using power output (PO) and heart rate (HR) data, we aimed to compare the racing demands of successful (at least top-5) and less successful (at least top-15) cyclists during Grand Tours. We identified Grand Tours in which we could compare cyclists who had attained a top-5 position (Top) with riders who also competed for the General Classification in the same race but attained a worse position (Non-Top, at least top 15). Different race-derived measures of physical demands (e.g., PO, kJ spent, training stress score, durability and repeatability measures, time in different PO/HR zones) were analyzed. Data from 9 Grand Tours, including 9 Top (average position 3rd, range 1st-5th) and 9 Non-Top cyclists (average position 9th, range 4th-12th) were available. Despite significant between-group differences in finishing time (86.2 ± 6.3 vs. 86.3 ± 6.3 h, p < 0.001), no differences were found for any of the analyzed outcomes, except for a slightly higher proportion of time spent at low PO levels (zone 1 (≤ 55% of functional threshold power)) in Top compared to Non-Top cyclists (60.9% ± 1.8% vs. 58.4% ± 2.5%, respectively, p = 0.011). In summary, achieving a top position during a Grand Tour does not necessarily imply overall higher physical demands compared to those cases in which cyclists attain a slightly lower position, which suggests that other factors (e.g., individual or team tactics) or metrics might have a greater influence.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/sms.70074 | DOI Listing |
Hemasphere
September 2025
Hématologie et Hémostase Clinique, CHU de Brest Brest France.
Accelerated-phase (AP) or blast-phase (BP) myeloproliferative neoplasms (MPNs) are associated with dismal prognosis, with non-curative therapies such as hypomethylating agents (HMAs) considered in patients not eligible for intensive therapy, while some studies advocate for combination therapy with either ruxolitinib (RUXO) or venetoclax (VEN). To assess the relationship between treatment modalities and outcome, herein, we report a multicentric cohort of 149 patients (median age, 75 years) with AP/BP MPN not eligible for intensive therapy and/or allogeneic hematopoietic cell transplantation who received azacitidine (AZA) alone ( = 60) or in combination ( = 89; VEN [ = 51], RUXO [ = 27], or both [ = 9], isocitrate dehydrogenase inhibitors [ = 2]) between January 2019 and October 2023. With a median follow-up of 15 months, the median overall survival of the full cohort was 8.
View Article and Find Full Text PDFNeurochirurgie
September 2025
Department of Pediatric Orthopedic Surgery, Regional University Hospital Center of Tours, France; Regional Epidemiology Unit Centre-Val de Loire, Regional University Hospital Center of Tours, France; Reference Center for Rare Diseases, Chiari and Vertebral and Spinal Cord Malformations (C-MAVEM) of
Objective: Epidemiological data on rare spinal cord malformations in children are lacking in France. Using the national hospital discharge database (PMSI), we studied the care trajectories and estimated the morbidity and mortality burden of these conditions.
Study Design: We conducted a nationwide historical cohort study from 2010 to 2020, including children diagnosed with rare spinal cord diseases within the scope of the C-MAVEM network.
BMJ Open
September 2025
Departement of Neonatal Medicine and Pediatric Critical Care Medecine, Brest University Hospital Centre, Brest, Bretagne, France
Introduction: Preterm infants are at risk of developmental impairment, especially those born before 33 weeks gestational age. Many studies have shown a positive impact of early interventions on medical outcomes during hospitalisation, long-term cognitive development and parental anxiety. Infant Behavioral Assessment and Intervention Program (IBAIP) has shown positive effects on cognitive development but also on motor impairment in a Dutch cohort.
View Article and Find Full Text PDFBMJ Open
September 2025
Université Paris Cité, Paris, Île-de-France, France.
Objective: Advanced or recurrent endometrial carcinoma (EC) represents a significant clinical challenge. This study aimed to evaluate patient (age and comorbidities) and disease (histological subtypes and stages) characteristics, treatment patterns and survival outcomes in a real-world French healthcare setting.
Methods And Analysis: In this national, multi-centre, retrospective observational cohort study, 200 patients with advanced or recurrent EC receiving first- or second-line chemotherapy during the year 2019 were analysed.
Haemophilia
September 2025
Service d'Hématologie Biologique et d'Hémostase clinique, Hospices Civils De Lyon, UR4609 Université Claude Bernard Lyon 1, Lyon, France.
Introduction: Discrepancies in factor IX activity (FIX:C) measurements between one-stage clotting assays (OSAs) have been observed following infusion with recombinant factor IX extended half-life concentrates (EHL-rFIX) in the treatment of haemophilia B. These variations, primarily due to differences in activated partial thromboplastin time (APTT) reagents, complicate clinical decision-making.
Objectives: The aim of this study was to evaluate whether drug-specific calibrations for albumin-fused recombinant FIX (rFIX-FP) and Fc-fused recombinant FIX (rFIX-Fc) could reduce inter-reagent discrepancies.